Targeting the PD-1/PD-L1 axis for cancer treatment: a review on nanotechnology
Although nanomedicines have been in the oncology field for almost three decades with the introduction of doxil, only a few nanomedicine products have reached approval. Can nanotechnology be a realistic tool to reduce the number of hospital beds? At present, several clinically approved anti-PD-1/PD-L...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Royal Society
2022-04-01
|
| Series: | Royal Society Open Science |
| Subjects: | |
| Online Access: | https://royalsocietypublishing.org/doi/10.1098/rsos.211991 |
| _version_ | 1797837564493692928 |
|---|---|
| author | Tuan Hiep Tran Thi Thu Phuong Tran |
| author_facet | Tuan Hiep Tran Thi Thu Phuong Tran |
| author_sort | Tuan Hiep Tran |
| collection | DOAJ |
| description | Although nanomedicines have been in the oncology field for almost three decades with the introduction of doxil, only a few nanomedicine products have reached approval. Can nanotechnology be a realistic tool to reduce the number of hospital beds? At present, several clinically approved anti-PD-1/PD-L1 antibodies or CAR T cell-based therapies are available; however, the immunotherapy field is far from mature. Will immunotherapy be the fourth pillar of cancer treatment? In this review, we summarized the current status of immunotherapy using PD-1/PD-L1-targeting nanocarriers. The knowledge on material science, therapeutic agents and formulation designs could pave the way for high-efficacy treatment outcomes. |
| first_indexed | 2024-04-09T15:27:50Z |
| format | Article |
| id | doaj.art-5b80f0616e894c9dad8b956b74fb4098 |
| institution | Directory Open Access Journal |
| issn | 2054-5703 |
| language | English |
| last_indexed | 2024-04-09T15:27:50Z |
| publishDate | 2022-04-01 |
| publisher | The Royal Society |
| record_format | Article |
| series | Royal Society Open Science |
| spelling | doaj.art-5b80f0616e894c9dad8b956b74fb40982023-04-28T11:05:35ZengThe Royal SocietyRoyal Society Open Science2054-57032022-04-019410.1098/rsos.211991Targeting the PD-1/PD-L1 axis for cancer treatment: a review on nanotechnologyTuan Hiep Tran0Thi Thu Phuong Tran1Faculty of Pharmacy, PHENIKAA University, Hanoi 12116, VietnamDepartment of Life Sciences, University of Science and Technology of Hanoi Vietnam Academy of Science and Technology, Hanoi, VietnamAlthough nanomedicines have been in the oncology field for almost three decades with the introduction of doxil, only a few nanomedicine products have reached approval. Can nanotechnology be a realistic tool to reduce the number of hospital beds? At present, several clinically approved anti-PD-1/PD-L1 antibodies or CAR T cell-based therapies are available; however, the immunotherapy field is far from mature. Will immunotherapy be the fourth pillar of cancer treatment? In this review, we summarized the current status of immunotherapy using PD-1/PD-L1-targeting nanocarriers. The knowledge on material science, therapeutic agents and formulation designs could pave the way for high-efficacy treatment outcomes.https://royalsocietypublishing.org/doi/10.1098/rsos.211991PD-1/PD-L1nanoparticlesimmunotherapycancer treatmentcombination therapy |
| spellingShingle | Tuan Hiep Tran Thi Thu Phuong Tran Targeting the PD-1/PD-L1 axis for cancer treatment: a review on nanotechnology Royal Society Open Science PD-1/PD-L1 nanoparticles immunotherapy cancer treatment combination therapy |
| title | Targeting the PD-1/PD-L1 axis for cancer treatment: a review on nanotechnology |
| title_full | Targeting the PD-1/PD-L1 axis for cancer treatment: a review on nanotechnology |
| title_fullStr | Targeting the PD-1/PD-L1 axis for cancer treatment: a review on nanotechnology |
| title_full_unstemmed | Targeting the PD-1/PD-L1 axis for cancer treatment: a review on nanotechnology |
| title_short | Targeting the PD-1/PD-L1 axis for cancer treatment: a review on nanotechnology |
| title_sort | targeting the pd 1 pd l1 axis for cancer treatment a review on nanotechnology |
| topic | PD-1/PD-L1 nanoparticles immunotherapy cancer treatment combination therapy |
| url | https://royalsocietypublishing.org/doi/10.1098/rsos.211991 |
| work_keys_str_mv | AT tuanhieptran targetingthepd1pdl1axisforcancertreatmentareviewonnanotechnology AT thithuphuongtran targetingthepd1pdl1axisforcancertreatmentareviewonnanotechnology |